Skip Navigation



QJM Advance Access published online on June 24, 2009
QJM, doi:10.1093/qjmed/hcp071
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
102/8/523    most recent
hcp071v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bramham, K.
Right arrow Articles by Thompson, A.J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bramham, K.
Right arrow Articles by Thompson, A.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The non-invasive biopsy—will urinary proteomics make the renal tissue biopsy redundant?

K. Bramham1, H.D. Mistry1, L. Poston1, L.C. Chappell1 and A.J. Thompson2

From the 1Maternal and Fetal Research Unit and 2MRC Centre for Neurodegeneration Research, King's College, London, UK

Address correspondence to Dr K. Bramham, MRCP, Maternal and Fetal Research Unit, KCL Division of Reproduction and Endocrinology, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, UK. email: kate.bramham{at}kcl.ac.uk


  Abstract

Proteomics is a rapidly advancing technique which gives functional insight into gene expression in living organisms. Urine is an ideal medium for study as it is readily available, easily obtained and less complex than other bodily fluids. Considerable progress has been made over the last 5 years in the study of urinary proteomics as a diagnostic tool for renal disease. Advantages over the traditional renal biopsy include accessibility, safety, the possibility of serial sampling and the potential for non-invasive prognostic and diagnostic monitoring of disease and an individual's response to treatment. Urinary proteomics is now moving from a discovery phase in small studies to a validation phase in much larger numbers of patients with renal disease. Whilst there are still some limitations in methodology, which are assessed in this review, the possibility of urinary proteomics replacing the invasive tissue biopsy for diagnosis of renal disease is becoming an increasingly realistic option.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.